ETNB Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to 89bio's net margin of --. 89bio's return on equity of -- beat Perspective Therapeutics's return on equity of --.

89bio has a consensus price target of $27.55, signalling upside risk potential of 398.11%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Perspective Therapeutics has higher upside potential than 89bio, analysts believe Perspective Therapeutics is more attractive than 89bio.

89bio has a beta of 1.296, which suggesting that the stock is 29.643% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. 89bio's net income of -$118.4M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, 89bio's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -57.51%. 89bio's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -63.91%.

89bio has a consensus price target of $27.55, signalling upside risk potential of 398.11%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $414.07 which suggests that it could grow by 30.56%. Given that 89bio has higher upside potential than Madrigal Pharmaceuticals, analysts believe 89bio is more attractive than Madrigal Pharmaceuticals.

89bio has a beta of 1.296, which suggesting that the stock is 29.643% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.683, suggesting its less volatile than the S&P 500 by 168.299%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $103.3M. 89bio's net income of -$118.4M is lower than Madrigal Pharmaceuticals's net income of -$59.4M. Notably, 89bio's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -- compared to 89bio's net margin of -117.16%. 89bio's return on equity of -- beat Moderna's return on equity of -29.09%.

89bio has a consensus price target of $27.55, signalling upside risk potential of 398.11%. On the other hand Moderna has an analysts' consensus of $52.05 which suggests that it could grow by 98.66%. Given that 89bio has higher upside potential than Moderna, analysts believe 89bio is more attractive than Moderna.

89bio has a beta of 1.296, which suggesting that the stock is 29.643% more volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than Moderna quarterly revenues of $956M. 89bio's net income of -$118.4M is higher than Moderna's net income of -$1.1B. Notably, 89bio's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 3.18x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to 89bio's net margin of -49.65%. 89bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

89bio has a consensus price target of $27.55, signalling upside risk potential of 398.11%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 60.41%. Given that 89bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe 89bio is more attractive than NovaBay Pharmaceuticals.

89bio has a beta of 1.296, which suggesting that the stock is 29.643% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

89bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. 89bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

89bio quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. 89bio's net income of -$118.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, 89bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for 89bio is -- versus 0.14x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.